ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42489683

Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.

Piha-Paul SA and 14 others. Clin Cancer Res, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial. Papers, record 42489683. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42489683

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2026
PubMed
Publication types
Journal Article, Clinical Trial, Phase I, Multicenter Study, Clinical Trial, Phase II
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-11-05
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Piha-Paul SASarina Ahttps://orcid.org/0000-0001-9455-1660
2Liao CYChih-Yihttps://orcid.org/0000-0002-5114-3162
3Dayyani FFarshidhttps://orcid.org/0000-0002-4970-5189
4Gabrail NYNashat Yhttps://orcid.org/0009-0007-3885-3622
5Kazmi SMASyed Mohammad Alihttps://orcid.org/0000-0002-3367-367X
6Lavasani SMSayeh Moazamihttps://orcid.org/0000-0002-3659-1960
7Hennessy KKatiehttps://orcid.org/0009-0005-1899-4642
8Ni SShumaohttps://orcid.org/0000-0001-6891-2936
9Sun CCaixiahttps://orcid.org/0009-0009-9426-4157
10Wang HHuihttps://orcid.org/0009-0004-5700-5934

1 to 10 of 15Source PubMed

See all 15 authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Male
Female
Aged
Middle Aged
Adult
Aged, 80 and over
Treatment Outcome

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131,774,688Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.J Clin Oncol2020https://conductscience.org/library/papers/31774688PubMed
238,297,981First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.Oncologist2024https://conductscience.org/library/papers/38297981PubMed
339,394,434The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.Nat Cancer2024https://conductscience.org/library/papers/39394434PubMed
439,706,336A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Ann Oncol2025https://conductscience.org/library/papers/39706336PubMed
538,048,851
In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Eur J Pharm Sci2024https://conductscience.org/library/papers/38048851PubMed
625,932,675Targeting cancer with kinase inhibitors.J Clin Invest2015https://conductscience.org/library/papers/25932675PubMed
739,702,163Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.Cancer Cell Int2024https://conductscience.org/library/papers/39702163PubMed
836,115,852Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.Signal Transduct Target Ther2022https://conductscience.org/library/papers/36115852PubMed
938,216,005Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.Pharmacol Res2024https://conductscience.org/library/papers/38216005PubMed
1021,612,468Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med2011https://conductscience.org/library/papers/21612468PubMed

1 to 10 of 18

See all 18 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

None in this release.

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AR367PubTator's text mininghttps://conductscience.org/library/genes/367NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene
KDR3,791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KMT2A4,297PubTator's text mininghttps://conductscience.org/library/genes/4297NCBI Gene
MYC4,609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
ROS16,098PubTator's text mininghttps://conductscience.org/library/genes/6098NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42489683

GET https://conductscience.org/api/papers/v1/42489683/authors

API referenceFor AI assistants